IP Library Granted Patent US 9,427,586
Granted Patent B2
US 9,427,586 · App. 13/957,499 · Granted Aug 30, 2016

Methods and apparatus to stimulate heart atria

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,427,586
App. No.
13/957,499
Granted
Aug 30, 2016
Kind
B2
Abstract

A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.

Claims (41)

1. A method for pacing a heart of a patient suffering from hypertension or sodium retention, the method comprising:

artificially pacing an atrium of the heart during a period between an end of an atrial refractory period and an end of a ventricular refractory period;

wherein the artificial pacing causes the atrium of the heart to contract against a closed heart valve of the atrium such that the contraction distends a wall of the atrium with blood; and

wherein the distention of the wall results in a therapeutic effect of a reduction in blood pressure.

2. The method of claim 1 , further comprising pacing a ventricle of the heart.

3. The method of claim 1 , further comprising pacing a ventricle of the heart at a first rate and pacing the atrium at a second rate that is faster than the first rate.

4. The method of claim 1 , further comprising alternating between a first pacing period of time that comprises the atrium contracting against the closed heart valve and a second pacing period of time that is different from the first pacing period.

5. The method of claim 4 , wherein the second pacing period comprises synchronous atria-ventricular pacing.

6. The method of claim 1 , wherein artificially pacing the atrium comprises cyclically: (a) applying artificially induced contractions of the atrium and (b) allowing naturally occurring contractions of the atrium.

7. The method of claim 1 , wherein the artificial pacing causes the atrium to contract between a middle and an end of ventricular systole.

8. The method of claim 1 , wherein the artificial pacing causes the atrium to contract at or after a middle of ventricular systole when the atrium is distended by passive filling with blood and the heart valve is closed.

9. The method of claim 1 , wherein the artificial pacing causes the atrium to contract when the heart valve is closed by a ventricular pressure that exceeds a pressure of the atrium.

10. The method of claim 1 , wherein the therapeutic effect comprises a reduction in at least one of vasoconstriction and sodium retention.

11. A method for pacing a heart of a patient suffering from hypertension or sodium retention, the method comprising:

delivering an excitatory stimulation to an atrium of the heart during a period between an end of an atrial refractory period and an end of a ventricular refractory period;

causing, with the excitatory stimulation, the atrium of the heart to contract against a closed heart valve of the atrium;

causing, with the contraction of the atrium, a pressure rise within the atrium that distends a wall of the atrium;

causing, with the distention of the wall of the atrium, stress of muscle of the wall of the atria; and

causing, with the stress of the muscle of the wall of the atria, at least one of release of atrial hormones and vagal neuro activation, resulting in a therapeutic effect of a reduction in blood pressure.

12. The method of claim 11 , wherein the therapeutic effect comprises a reduction in at least one of vasoconstriction and sodium retention.

13. The method of claim 11 , further comprising pacing a ventricle of the heart.

14. The method of claim 11 , further comprising pacing a ventricle of the heart at a first rate and pacing the atrium at a second rate that is faster than the first rate.

15. The method of claim 11 , further comprising alternating between a first pacing period of time that comprises the atrium contracting against the closed heart valve and a second pacing period of time that is different from the first pacing period.

16. The method of claim 15 , wherein the second pacing period comprises synchronous atria-ventricular pacing.

17. The method of claim 11 , wherein the excitatory stimulation is delivered to the atrium between a middle and an end of ventricular systole.

18. The method of claim 11 , wherein the excitatory stimulation is delivered to the atrium at or after a middle of ventricular systole when the atrium is distended by passive filling with blood and the heart valve is closed.

19. The method of claim 11 , wherein the heart valve is closed by a ventricular pressure that exceeds a pressure of the atrium.

20. The method of claim 11 , wherein the excitatory stimulation causes the atrium to contract when the heart valve is closed by a ventricular pressure that exceeds a pressure of the atrium.

21. A programmable implantable pacemaker connectable to at least one electrically conductive lead for connecting to a heart of a patient, the pacemaker being programmed to generate electrical signals to be conveyed to the heart through the at least one electrically conductive lead, such that the electrical signals artificially pace an atrium of the heart;

wherein the generated electrical signals are configured to deliver excitatory stimulation to the heart following an end of an atrial refractory period and before an end of a ventricular refractory period; and

wherein the excitatory stimulation is configured to cause the atrium to contract against a closed heart valve associated with the atrium such that the contraction distends the atrium with blood, and the distending atrium results in a therapeutic effect of a reduction in blood pressure.

22. The pacemaker of claim 21 , wherein the pacemaker is programmed to sense electrical signals generated by the heart and conveyed to the programmable implantable pacemaker through the at least one electrically conductive lead, and based on the sensed electrical signals, determine the atrial refractory period and the ventricular refractory period.

23. The pacemaker of claim 21 , wherein the pacemaker is programmed to deliver the excitatory stimulation when the heart valve is closed by a ventricular pressure that exceeds a pressure of the atrium.

24. The pacemaker of claim 21 , wherein the pacemaker is programmed to alternate between a first pacing period of time that comprises the atrium contracting against the closed heart valve and a second pacing period of time that comprises synchronous atria-ventricular pacing.

25. The pacemaker of claim 21 , wherein the pacemaker is programmed to artificially pace the atrium by cyclically: (a) causing artificially induced contractions of the atrium and (b) allowing naturally occurring contractions of the atrium.

26. The pacemaker of claim 21 , wherein the pacemaker is programmed to deliver the excitatory stimulation at or after a middle of ventricular systole when the atrium is distended by passive filling with blood and the heart valve is closed.

27. The pacemaker of claim 21 , wherein the pacemaker is programmed to pace a ventricle of the heart.

28. The pacemaker of claim 21 , wherein the pacemaker is programmed to pace a ventricle of the heart at a first rate and pace the atrium at a second rate that is faster than the first rate.

29. The pacemaker of claim 21 , wherein the excitatory stimulation causes the atrium to contract between a middle and an end of ventricular systole.

30. The pacemaker of claim 21 , wherein the therapeutic effect comprises a reduction in at least one of vasoconstriction and sodium retention.

31. The pacemaker of claim 21 , further comprising one or more electrically conductive leads connected to the pacemaker.

Assignments (7)
SECURITY INTEREST Recorded Aug 7, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: MEDTRONIC, INC.
Reel/Frame 072341/0075 →
SECURITY INTEREST Recorded Aug 4, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: LIGAND PHARMACEUTICALS, INC.
Reel/Frame 072359/0219 →
SECURITY INTEREST Recorded Nov 6, 2024
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC
To: HERCULES CAPITAL, INC.
Reel/Frame 069312/0758 →
SECURITY AGREEMENT Recorded Jun 6, 2022
From: ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC; ACCELERATED TECHNOLOGIES, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 060286/0021 →
ENTITY CONVERSION Recorded Feb 13, 2020
From: BACKBEAT MEDICAL, INC.
To: BACKBEAT MEDICAL, LLC
Reel/Frame 051930/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: LEVIN, HOWARD; GELFAND, MARK
To: G&L CONSULTING, LLC
Reel/Frame 031461/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: G&L CONSULTING, LLC
To: BACKBEAT MEDICAL, INC.
Reel/Frame 031461/0649 →